Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Summary

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

Timeline

Start

2024-05-24

Primary completion

2026-06-30

Completion

2028-12-30

Drugs

Indications